Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering.Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public offering…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
